INTRODUCTION: Previous studies have suggested that young breast cancer patients have poorer survival as compared with their older counterparts. Most of this research reflects single institution experiences that may not be representative of the population. This study was designed to determine whether young breast cancer patients have poorer survival as compared with an older cohort using a national population-based cancer registry and, more specifically, to determine whether differences in survival are caused by more advanced tumor stage, more aggressive disease, or patient-specific characteristics. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results cancer database (1992-1998), data for all patients with a diagnosis of invasive breast cancer were extracted. Two age categories were analyzed: young group (<or=35 years old, n = 4616) and older group (50-55 years old, n = 20319). Patient demographics, 5-year survival rates, tumor characteristics (stage, grade, and receptor status), surgical treatment, and use of radiation were compared between the groups. RESULTS: Overall, young patients had worse 5-year survival when compared with the older group (74.3% vs. 85.1%). Stage for stage, the young patients also had poorer survival (except for stage IV). They present with more advanced stage disease and have more aggressive tumor characteristics, that is, higher grade tumors and more estrogen- and progesterone receptor-negative tumors. Even after controlling for patient characteristics, tumor factors, and receipt of treatment, a multivariate regression showed that young age was an independent risk factor for death (HR = 1.095). CONCLUSIONS: Young breast cancer patients have poorer outcomes, which are in part attributed to later stage disease, more aggressive tumors, and less favorable receptor status. There still appears to be other important factors, not included in our study, that are contributing to the worse outcomes for these young patients, such as socioeconomic status. Physicians need to have heightened awareness when evaluating this population, and increasingly efficacious adjuvant therapies need to be developed.
INTRODUCTION: Previous studies have suggested that young breast cancerpatients have poorer survival as compared with their older counterparts. Most of this research reflects single institution experiences that may not be representative of the population. This study was designed to determine whether young breast cancerpatients have poorer survival as compared with an older cohort using a national population-based cancer registry and, more specifically, to determine whether differences in survival are caused by more advanced tumor stage, more aggressive disease, or patient-specific characteristics. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results cancer database (1992-1998), data for all patients with a diagnosis of invasive breast cancer were extracted. Two age categories were analyzed: young group (<or=35 years old, n = 4616) and older group (50-55 years old, n = 20319). Patient demographics, 5-year survival rates, tumor characteristics (stage, grade, and receptor status), surgical treatment, and use of radiation were compared between the groups. RESULTS: Overall, young patients had worse 5-year survival when compared with the older group (74.3% vs. 85.1%). Stage for stage, the young patients also had poorer survival (except for stage IV). They present with more advanced stage disease and have more aggressive tumor characteristics, that is, higher grade tumors and more estrogen- and progesterone receptor-negative tumors. Even after controlling for patient characteristics, tumor factors, and receipt of treatment, a multivariate regression showed that young age was an independent risk factor for death (HR = 1.095). CONCLUSIONS: Young breast cancerpatients have poorer outcomes, which are in part attributed to later stage disease, more aggressive tumors, and less favorable receptor status. There still appears to be other important factors, not included in our study, that are contributing to the worse outcomes for these young patients, such as socioeconomic status. Physicians need to have heightened awareness when evaluating this population, and increasingly efficacious adjuvant therapies need to be developed.
Authors: Gertraud Maskarinec; Ian Pagano; Galina Lurie; Erin Bantum; Carolyn C Gotay; Brian F Issell Journal: J Womens Health (Larchmt) Date: 2011-01-31 Impact factor: 2.681
Authors: Justin G Trogdon; Donatus U Ekwueme; Diana Poehler; Cheryll C Thomas; Katherine Reeder-Hayes; Benjamin T Allaire Journal: Breast Cancer Res Treat Date: 2017-07-12 Impact factor: 4.872
Authors: Winnie Yeo; Hang-Mei Lee; Amy Chan; Emily Yy Chan; Miranda Cm Chan; Keeng-Wai Chan; Sharon Ww Chan; Foon-Yiu Cheung; Polly Sy Cheung; Peter Hk Choi; Josette Sy Chor; William Wl Foo; Wing-Hong Kwan; Stephen Ck Law; Lawrence Pk Li; Janice Wh Tsang; Yuk Tung; Lorna Ls Wong; Ting-Ting Wong; Chun-Chung Yau; Tsz-Kok Yau; Benny Cy Zee Journal: World J Clin Oncol Date: 2014-12-10
Authors: Benjamin T Allaire; Donatus U Ekwueme; Diana Poehler; Cheryll C Thomas; Gery P Guy; Sujha Subramanian; Justin G Trogdon Journal: Breast Cancer Res Treat Date: 2017-04-21 Impact factor: 4.872
Authors: Megan Greally; Jennifer Kielty; Geoffrey A Watson; Geoffrey Das; Christina Malouf; Lynda McSorley; Niamh Coleman; Cecily Quinn; Enda W McDermott; Giuseppe Gullo; John Crown; Ruth S Prichard; Catherine M Kelly; Janice M Walshe Journal: Ir J Med Sci Date: 2018-05-15 Impact factor: 1.568
Authors: Hanna Fredholm; Sonja Eaker; Jan Frisell; Lars Holmberg; Irma Fredriksson; Henrik Lindman Journal: PLoS One Date: 2009-11-11 Impact factor: 3.240